The Most Effective Weight Loss Medication Ever Studied
Tirzepatide — sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity) — has produced weight loss results in clinical trials that were previously thought impossible with medication alone. In the landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, participants receiving the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks — compared to 3.1% in the placebo group.[1] More than half of participants on the 10 mg and 15 mg doses lost at least 20% of their body weight.[1]
To put that in context: a 200-pound person on the 15 mg dose would be expected to lose approximately 42 pounds over 18 months. These are numbers that previously required bariatric surgery to achieve.
Three-year follow-up data from the same trial, published in late 2024, showed that results were largely sustained — and that tirzepatide reduced the onset of type 2 diabetes in participants with prediabetes from 13.3% in the placebo group to just 0.4% in the 15 mg group.[2]
How Tirzepatide Works: The Dual Mechanism
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first medication of its class. It simultaneously activates two incretin hormone pathways: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).[3]
GLP-1 activation — the mechanism shared with semaglutide (Ozempic/Wegovy) — suppresses appetite, slows gastric emptying (so you feel full longer), and improves insulin secretion. GIP activation adds a complementary layer: it enhances insulin sensitivity in fat tissue and may reduce some of the gastrointestinal side effects associated with GLP-1 agonism alone, which is one reason tirzepatide tends to be better tolerated than semaglutide at equivalent weight-loss doses.[3]
The synergy between these two pathways is what drives tirzepatide's superior efficacy. In a large real-world comparative study published in JAMA Internal Medicine, patients on tirzepatide were 1.76 times more likely to achieve at least 5% weight loss and 2.54 times more likely to achieve at least 10% weight loss compared to patients on semaglutide — after controlling for baseline characteristics.[4]
What Happens When You Stop
One of the most important findings from the clinical trial program is what happens when tirzepatide is discontinued. The SURMOUNT-4 trial followed participants who had lost weight on tirzepatide and then were randomized to either continue the medication or switch to placebo. Those who continued treatment maintained their weight loss and actually lost an additional 5.5% over the following year; those who switched to placebo regained most of the weight they had lost.[5]
This is not a failure of the medication — it reflects the underlying biology of obesity. The body has powerful homeostatic mechanisms that drive weight regain when caloric restriction is removed. Tirzepatide works by modifying the hormonal signals that regulate appetite and energy balance; when those signals are no longer being modified, the original dysregulation reasserts itself.
The clinical implication is that tirzepatide, for most patients, is a long-term treatment — not a short-term intervention. This is why the broader metabolic context matters so much.
The Med Spa Model vs. the Medical Model
Tirzepatide has become widely available through medical spas, telehealth platforms, and weight loss clinics that offer rapid prescriptions with minimal evaluation. A patient can often obtain a prescription after a brief online questionnaire and a BMI check. This approach gets the medication into patients' hands quickly — but it misses the clinical work that determines whether tirzepatide is appropriate, what dose is right, and what else needs to be addressed for the results to be meaningful and sustainable.
At PeakLAB, a Mounjaro or Zepbound evaluation begins with a comprehensive metabolic and hormonal workup. This matters for several reasons. First, metabolic dysfunction rarely exists in isolation. Patients seeking weight loss frequently have underlying thyroid dysfunction, insulin resistance, cortisol dysregulation, or sex hormone imbalances that are contributing to their difficulty losing weight — and that will limit the effectiveness of any medication if left unaddressed. Second, GLP-1 medications interact with other hormonal systems. Thyroid function, in particular, should be evaluated before and during treatment. Third, the side effect profile — primarily gastrointestinal symptoms during dose escalation — is manageable with the right titration strategy and clinical support, but requires a physician who is engaged and accessible.
The medication is a tool. The clinical relationship is what makes it work.
Who Is a Good Candidate?
Tirzepatide is FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia). In the SURMOUNT-1 trial, the mean participant age was 44.9 years, 67.5% were female, and the mean BMI was 38.0 kg/m².[1]
Good candidates are those who have made genuine efforts at lifestyle modification and have not achieved or sustained meaningful weight loss — not because of lack of effort, but because of the underlying hormonal and metabolic dysregulation that makes weight loss physiologically difficult for many people. Tirzepatide addresses the hormonal side of that equation; the lifestyle work remains essential for long-term success.
Tirzepatide is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or for those with a history of pancreatitis. A thorough medical history is essential before prescribing.
Mounjaro at PeakLAB Medicine in Fort Collins
PeakLAB offers tirzepatide (Mounjaro/Zepbound) as part of a comprehensive metabolic medicine program — not as a standalone prescription. Every patient starts with a full evaluation: lab work, health history, hormone assessment, and a conversation about goals and expectations. Treatment is individualized, monitored, and adjusted over time.
We see patients via telemedicine across Colorado, Arizona, Nebraska, and Wyoming. If you're in Fort Collins or anywhere in Colorado and want to understand whether tirzepatide is right for you, a free discovery call is the best place to start.
References
- Jastreboff AM, Aronne LJ, Ahmed NN, et al. (SURMOUNT-1 Investigators). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
- Jastreboff AM, le Roux CW, Stefanski A, et al. (SURMOUNT-1 Investigators). Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2024;Nov 13 [Epub ahead of print].
- Liu QK, et al. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292.
- Jastreboff AM, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1017–1026.
- Aronne LJ, et al. (SURMOUNT-4). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38–48.
This content is for educational purposes only and does not constitute medical advice. Weight loss medication decisions should be made in consultation with a qualified physician who can evaluate your individual health history, metabolic profile, and treatment goals.
PeakLAB Medicine is an independent integrative medicine practice in Fort Collins, Colorado. Dr. Lindsey Bailey, DO is board certified in Emergency Medicine and Integrative Medicine and sees patients via telemedicine across Colorado, Arizona, Nebraska, and Wyoming. To schedule a consultation, visit peaklabmed.com.
